- Home
- SGLY vs RDHL Comparison
SGLY vs RDHL Comparison
Compare SGLY & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | RDHL |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.6M |
| IPO Year | 2008 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SGLY | RDHL |
|---|---|---|
| Price | $0.40 | $0.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.6K | 29.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,813,193.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.88 |
| 52 Week High | $1.86 | $3.31 |
Technical Indicators
Market Signals| Indicator | SGLY | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 35.35 |
| Support Level | $0.34 | $0.91 |
| Resistance Level | $0.43 | $1.07 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.24 | 16.80 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.